Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

26,450 signal articles · 282 in last 24h · 126,894 total before filter · latest 29m ago
282last 24h
1230last 7d
194● bullish (7d)
122● bearish (7d)
205publishers
AllMacro239Earnings460M&A90Regulatory23Product12Analyst12
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
AI startup Manus to resume independent operations as deal with Meta unwinds
Reuters16d agoneutral
AI startup Manus to resume independent operations as deal with Meta unwinds

AI startup Manus said on Tuesday it will ‌resume operating as an independent company ‌and some user data will be deleted as ​part of its separation from U.S. tech giant Meta. • "As part of our transition back to independent operations and to comply ‌with regulatory requirements ⁠in specific jurisdictions, data generated by certain users on/after December ⁠29, 2025" will be deleted later this month, Manus said in a statement. • ​Affected users ​will be notified ​through the Manus ‌app and by email and will be able to back up their data, the company said.

Rocket Lab Drops on Launch Pushback; Riot Platforms' Anthropic Deal | Stock Movers
Bloomberg16d agobearishVIDEO
Rocket Lab Drops on Launch Pushback; Riot Platforms' Anthropic Deal | Stock Movers

On this episode of Stock Movers: - Anthropic PBC has struck a $9.1 billion deal with Riot Platforms (RIOT), a Bitcoin mining company that recently began selling AI data center capacity. Riot disclosed it had secured a 20-year deal to supply 191 megawatts of capacity from its Rockdale, Texas, campus to a "leading frontier AI" company. - Rocket Lab (RKLB) shares drop as much as 5.7% after the company's Neutron timeline softened, with an analyst saying that while Neutron remains on track to reach launch pad in the fourth quarter, it could push an initial launch to 2027. - Babcock & Wilcox Enterprises (BW) rose in premarket after the company signed an agreement with Siemens Energy to produce steam turbine generator sets. - US-listed shares in On Holding (ONON) drop as much as 17% in premarket trading after the Swiss sneaker maker's second-quarter sales were lower than expected.

Procter & Gamble (PG) Issues 2027 Guidance, Is The Stock Expensive?
Simply Wall St.16d agoneutral
Procter & Gamble (PG) Issues 2027 Guidance, Is The Stock Expensive?

Procter & Gamble (PG) has just updated investors with full year 2027 guidance, new quarterly earnings expectations, and fresh details on capital returns, including dividends and share buybacks, all released alongside its latest annual results. See our latest analysis for Procter & Gamble. At a share price of $146.44, Procter & Gamble has seen a 3.28% year to date share price return, while the 1 year total shareholder return is down 2.73%. This signals momentum that is still relatively muted...

Should Costco’s Double‑Digit July Sales and New Brand Rollouts Prompt Action From Costco Wholesale (COST) Investors?
Simply Wall St.16d agoneutral
Should Costco’s Double‑Digit July Sales and New Brand Rollouts Prompt Action From Costco Wholesale (COST) Investors?

In early August 2026, Costco Wholesale reported July net sales of US$23.12 billion, up 10.7% year over year, and US$273.55 billion in net sales for the first forty‑eight weeks, a 10.1% increase, while brands like Physician's Choice and Mighty Spark Food Company announced nationwide product rollouts across Costco’s U.S. warehouses. These results highlight Costco’s ability to grow high‑volume membership sales while attracting new branded offerings, reinforcing its role as a key distribution...

AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 Data
Simply Wall St.16d agoneutral
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 Data

AbCellera Biologics (NasdaqGS:ABCL) reports positive top line Phase 2 results for ABCL635, its non hormonal antibody treatment for moderate to severe menopausal vasomotor symptoms. The trial shows clinically significant improvement in vasomotor symptoms from a single dose of ABCL635. ABCL635 represents the first clinical success from AbCellera's internal pipeline and supports its GPCR and ion channel antibody discovery platform. The outcome may influence AbCellera's future plans for internal...

Cisco (CSCO) Puts 90,000 Workers On Personalized AI Agents With New Revenue Targets
Simply Wall St.16d agoneutral
Cisco (CSCO) Puts 90,000 Workers On Personalized AI Agents With New Revenue Targets

Cisco Systems (NasdaqGS: CSCO) is rolling out personalized AI agents to its entire 90,000-person workforce as part of a broad internal transformation. The company is pairing the deployment with major infrastructure investment and company-wide model routing to manage AI workloads across teams and functions. Cisco is setting defined AI-driven revenue targets, tying the internal rollout to measurable business outcomes and new income streams. The move signals a push to use standardized agentic...

KLA (KLAC) Is Up 5.5% After Strong Earnings, AI-Driven Outlook And Dividend Hike - What's Changed
Simply Wall St.16d agoneutral
KLA (KLAC) Is Up 5.5% After Strong Earnings, AI-Driven Outlook And Dividend Hike - What's Changed

KLA Corporation recently declared a quarterly cash dividend of US$0.23 per share, payable on September 1, 2026, to shareholders of record as of August 17, 2026, alongside reporting higher quarterly and full-year revenue and earnings through June 30, 2026, and issuing guidance for the September 2026 quarter. These results and guidance arrive as semiconductor equipment demand is being reinforced by large AI chip manufacturing projects like Tesla and SpaceX’s Terafab complex and by industry...

Goldman Sachs (GS) Stock May Be A Bargain On Earnings But Fairly Valued Overall
Simply Wall St.16d agoneutral
Goldman Sachs (GS) Stock May Be A Bargain On Earnings But Fairly Valued Overall

Goldman Sachs Group stock has put in a very strong three year run, yet current valuation checks suggest the shares now sit closer to fair value than to a clear bargain. The Excess Returns intrinsic value estimate points to the stock being roughly in line with its assessed worth, while earnings based multiples still screen as supportive. Goldman Sachs Group has returned 228.6% over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Recent strength...